New Investigational Drug for Lupus Nephritis Receives Phase 1 Clearance from FDA
Kyverna Therapeutics’ application for an Investigational New Drug has been cleared by the Food and Drug Administration. In early 2023, researchers will initiate a Phase 1 clinical trial of the investigational drug KYV-101 for the treatment of lupus kidney disease (lupus nephritis (LN)).
KYV-101 is another version of CAR-T experimental cell therapy that aims to eliminate B cells to reduce inflammation. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.
Continue to follow the Lupus Foundation of America for updates on KYV-101 and learn more about medications used to treat lupus.
Interested in getting research like this straight to your inbox? Subscribe to our bimonthly Inside Lupus Research email for all the latest.Subscribe Now